SHANGHAI, NANJING, and SAN FRANCISCO, May 20, 2025 — IASO Biotherapeutics (“IASO Bio”), a biopharmaceutical firm dedicated to the discovery, development, manufacturing, and commercialization of cutting-edge cell therapies and antibody biologics, today commemorated the opening of its Global R&D Center in Shanghai’s Waigaoqiao Free Trade Zone (FTZ) and the successful completion of its industry forum, “Opportunities and Challenges of China’s Cell Therapy Globalization.”
The event attracted over 100 notable attendees, including Xu Lai, Shanghai Pudong New Area Deputy District Mayor, international experts from the UK, Russia, Mexico, Japan, Indonesia, and leading executives from China’s biopharmaceutical industry. Participants engaged in lively discussions regarding advancements in cell therapy and strategies for globalizing China’s cell therapy innovations.
Strategically situated in what is often referred to as “China’s gateway to the world,” the FTZ is recognized as one of China’s first pilot zones to authorize R&D and manufacturing of foreign-invested stem cell and gene therapy. The 32,000-square-meter IASO Bio Global R&D Center will leverage the zone’s favorable policies – including tariff benefits, streamlined customs clearance, and clinical trial support – to spearhead the development of next-generation cell and gene therapies. The facility will collaborate with IASO Bio’s Nanjing headquarters while promoting the company’s international growth.
Ms. Jinhua Zhang, Founder, Chairwoman, and CEO of IASO Bio, stated, “We are deeply grateful to the Pudong New Area government, Waigaoqiao Administration Bureau, and Waigaoqiao Group for their comprehensive support, encompassing infrastructure, funding, and premium services.” She added, “This support will enable our Global R&D Center to accelerate innovation. We also appreciate our global network of clinical experts, partners, and investors for joining us today. With Waigaoqiao as our strategic base, we are well-positioned to advance China’s cell therapy sector globally. IASO Bio remains committed to pushing scientific boundaries and delivering transformative therapies to patients worldwide.”
The inauguration ceremony concluded with attendees jointly activating a symbolic button representing innovation and hope, marking a new era of global development for IASO Bio.
During the event, IASO Bio announced strategic partnerships with organizations from Japan, Mexico, Russia, Indonesia, and China’s Shenzhen Canyou Group. These collaborations will focus on accelerating the international commercialization of CAR-T therapies and introducing innovative stem cell treatments to benefit a wider range of patients globally.
The accompanying forum included two insightful panel discussions:
- Global Synergy – Extending Access to Patients Worldwide
- Global Innovation – Next Generation of CGT Renowned experts from Europe, Asia, and the Americas shared region-specific insights, providing valuable information to guide the trajectory of China’s cell therapy industry.
About IASO Bio
IASO Bio is a biopharmaceutical company focused on the discovery and development of innovative cell therapies and biologics for oncology and autoimmune diseases. IASO Bio possesses comprehensive capabilities spanning the entire drug development process, from early discovery to clinical development, regulatory approval, and commercialization.
Its pipeline includes a diversified portfolio of over 10 novel products, including Equecabtagene Autoleucel (a fully human BCMA CAR-T injection). Equecabtagene Autoleucel received Biologics License Application (BLA) approval from China’s National Medical Products Administration (NMPA) in June 2023 and U.S. FDA IND approval for the treatment of R/RMM in December 2022.
Leveraging its strong management team, innovative product pipeline, as well as integrated and high quality manufactural and clinical capabilities, IASO aims to deliver transformative, curable, and affordable therapies that fulfil unmet medical needs to patients in China and around the world. For more information, please visit or .
SOURCE IASO Bio
“`